Prelude Therapeutics Incorporated announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026. Dr. Morris is a medical oncologist with over 30 years of oncology drug development experience working with global biotech and pharmaceutical companies and managing multiple drug approvals. Most recently, he served as Chief Medical Officer at Lava Therapeutics.
Prior to Lava Therapeutics, Dr. Morris served as Chief Medical Officer for Celyad Oncology, Radius Health, where he contributed to the development of ONSERDU (elacestrant) for breast cancer ImmunoGen ? advancing ELAHERE (mirvetuximab soravtansine) for ovarian cancer and Allos Therapeutics, where he contributed to all phases of development for solid and hematological tumor indications. He began his career at AstraZeneca and held roles of increasing responsibility including global medical lead for Faslodex (fulvestrant) which he helped manage through its approval for HR+/HER2- advanced breast cancer.Dr. Morris holds his medical degree and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from Sheffield University Medical School in the United Kingdom and is a Member of the Royal College of Physicians of London.
